These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19688158)

  • 21. Adalimumab treats psoriasis in patients previously treated with etanercept: a case series.
    Yamauchi PS; Mau N
    J Am Acad Dermatol; 2009 Jul; 61(1):158-60. PubMed ID: 19539861
    [No Abstract]   [Full Text] [Related]  

  • 22. New biologic therapies for psoriatic disease.
    Bohjanen KA; Prawer SE
    Minn Med; 2004 Mar; 87(3):34-6. PubMed ID: 15080292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Intermittent treatment regimens and the rational (efficient) use of biologic agents in psoriasis].
    Moreno-Ramírez D
    Actas Dermosifiliogr; 2011 May; 102(4):241-3. PubMed ID: 21481332
    [No Abstract]   [Full Text] [Related]  

  • 24. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients.
    Young MS; Horn EJ; Cather JC
    Expert Rev Clin Immunol; 2011 Jan; 7(1):9-13. PubMed ID: 21162644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis.
    Gualdi G; Monari P; Rossi MT; Crotti S; Calzavara-Pinton PG
    Br J Dermatol; 2012 Jun; 166(6):1373-4. PubMed ID: 22212112
    [No Abstract]   [Full Text] [Related]  

  • 26. Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome.
    Driessen RJ; Berends MA; Boezeman JB; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2008 May; 158(5):1098-106. PubMed ID: 18384440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
    JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immune-targeted antipsoriatic therapies.
    van Lingen RG; Körver JE; van de Kerkhof PC; Berends MA; van Rens DW; Langewouters AM; Boezeman JB; Seyger MM; de Jong EM
    Br J Dermatol; 2008 Jul; 159(1):91-6. PubMed ID: 18476954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of moderate to severe plaque psoriasis (part 2): clinical update on T-cell modulators and investigational agents.
    Sobell JM; Kalb RE; Weinberg JM
    J Drugs Dermatol; 2009 Mar; 8(3):230-8. PubMed ID: 19271369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Temporary interruption of treatment with etanercept].
    Ruiz-Genao DP; López-Estebaranz JL
    Actas Dermosifiliogr; 2010 May; 101 Suppl 1():102-5. PubMed ID: 20492889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching between antitumour necrosis factor alpha biologic agents--is patient weight an important consideration?
    Downs AM
    Br J Dermatol; 2009 May; 160(5):1123-4. PubMed ID: 19292716
    [No Abstract]   [Full Text] [Related]  

  • 32. Barriers to biologics.
    Weinberg JM
    Cutis; 2004 Sep; 74(3):164. PubMed ID: 15499757
    [No Abstract]   [Full Text] [Related]  

  • 33. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM; Saini R; Tutrone WD
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biologic therapy for psoriasis: a brief history, II.
    Tutrone WD; Kagen MH; Barbagallo J; Weinberg JM
    Cutis; 2001 Dec; 68(6):367-72. PubMed ID: 11775769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab.
    Puxeddu I; Giori L; Rocchi V; Bazzichi L; Bombardieri S; Tavoni A; Migliorini P; Del Corso I
    Ann Allergy Asthma Immunol; 2012 Feb; 108(2):123-4. PubMed ID: 22289732
    [No Abstract]   [Full Text] [Related]  

  • 36. Comment on "Development of monoclonal gammopathy in 12 patients receiving efalizumab treatment for chronic plaque psoriasis".
    Ginarte M
    J Am Acad Dermatol; 2011 Jun; 64(6):1184; author reply 1184-5. PubMed ID: 21571182
    [No Abstract]   [Full Text] [Related]  

  • 37. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
    Gaudin P
    Rev Med Interne; 2008 Dec; 29(12):971-4. PubMed ID: 18571291
    [No Abstract]   [Full Text] [Related]  

  • 38. [TNFalpha inhibitors for the treatment of rheumatoid arthritis].
    Sany J; Kaiser MJ
    Ann Med Interne (Paris); 2002 Feb; 153(1):34-40. PubMed ID: 11994688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM; Saini R
    Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor necrosis factor antagonists in the therapy of psoriasis.
    Mössner R; Schön MP; Reich K
    Clin Dermatol; 2008; 26(5):486-502. PubMed ID: 18755367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.